Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
SH3 domain containing GRB2 like 1, endophilin A2 | 0.686 | 0.346 | 1.2E-02 |
|
disease | 0.400 | None | 0 | 0 | |||||||||||
|
SH2B adaptor protein 3 | 0.527 | 0.692 | 1.0E-04 |
|
disease | 0.300 | None | 0 | 0 | |||||||||||
|
G protein-coupled receptor 183 | 0.700 | 0.462 | 1.7E-02 |
|
disease | 0.300 | None | 0 | 1 | |||||||||||
|
Cbl proto-oncogene C | 0.821 | 0.192 | 4.2E-11 |
|
disease | 0.300 | None | 0 | 0 | |||||||||||
|
GRINL1B complex locus 2 (pseudogene) | 1.000 | 0.038 |
|
disease | 0.300 | None | 0 | 0 | ||||||||||||
|
RAD21 cohesin complex component | 0.528 | 0.846 | 1.00 |
|
disease | 0.300 | None | 0 | 0 | |||||||||||
|
T cell immune regulator 1, ATPase H+ transporting V0 subunit a3 | 0.565 | 0.692 | 2.4E-13 |
|
disease | 0.100 | None | 0 | 0 | |||||||||||
|
DnaJ heat shock protein family (Hsp40) member C21 | 0.606 | 0.731 | 2.1E-07 |
|
disease | 0.100 | None | 0 | 1 | |||||||||||
|
erb-b2 receptor tyrosine kinase 3 | 0.448 | 0.808 | 1.7E-15 |
|
disease | 0.100 | None | 0 | 0 | |||||||||||
|
signal recognition particle 54 | 0.612 | 0.769 | 1.00 |
|
disease | 0.100 | None | 0 | 0 | |||||||||||
|
elongation factor like GTPase 1 | 0.638 | 0.577 | 5.1E-08 |
|
disease | 0.100 | None | 0 | 0 | |||||||||||
|
FA complementation group E | 0.553 | 0.808 | 1.5E-06 |
|
disease | 0.500 | strong | 1.000 | 1 | 0 | 2017 | 2017 | ||||||||
|
partner and localizer of BRCA2 | 0.485 | 0.769 | 3.0E-19 |
|
disease | 0.500 | strong | 1.000 | 1 | 0 | 2017 | 2017 | ||||||||
|
BRCA1 interacting protein C-terminal helicase 1 | 0.507 | 0.731 | 6.2E-17 |
|
disease | 0.500 | strong | 1.000 | 1 | 0 | 2017 | 2017 | ||||||||
|
cysteine rich hydrophobic domain 2 | 0.769 | 0.231 | 0.54 |
|
disease | 0.410 | None | 1.000 | 1 | 0 | 1999 | 1999 | ||||||||
|
LIM domain containing preferred translocation partner in lipoma | 0.543 | 0.769 | 7.2E-03 |
|
disease | 0.410 | None | 1.000 | 1 | 0 | 2001 | 2001 | ||||||||
|
protein tyrosine phosphatase receptor type T | 0.636 | 0.538 | 1.00 |
|
disease | 0.400 | None | 1.000 | 1 | 22 | 2017 | 2017 | ||||||||
|
CCAAT enhancer binding protein delta | 0.570 | 0.769 | 0.61 |
|
disease | 0.310 | None | 1.000 | 1 | 0 | 2007 | 2007 | ||||||||
|
EH domain containing 3 | 0.729 | 0.308 | 4.2E-02 |
|
disease | 0.310 | None | 1.000 | 1 | 0 | 2007 | 2007 | ||||||||
|
Cbl proto-oncogene B | 0.691 | 0.423 | 1.00 |
|
disease | 0.310 | None | 1.000 | 1 | 0 | 2007 | 2007 | ||||||||
|
IFI30 lysosomal thiol reductase | 0.700 | 0.423 | 3.0E-08 |
|
disease | 0.300 | None | 1.000 | 1 | 0 | 2007 | 2007 | ||||||||
|
mitotic arrest deficient 2 like 2 | 0.547 | 0.731 | 8.2E-02 |
|
disease | 0.300 | strong | 1.000 | 1 | 0 | 2017 | 2017 | ||||||||
|
growth arrest specific 2 like 1 | 0.861 | 0.077 | 0.83 |
|
disease | 0.300 | None | 1.000 | 1 | 0 | 2007 | 2007 | ||||||||
|
euchromatic histone lysine methyltransferase 2 | 0.590 | 0.808 | 1.0E-04 |
|
disease | 0.300 | None | 1.000 | 1 | 0 | 2014 | 2014 | ||||||||
|
V-set and immunoglobulin domain containing 4 | 0.628 | 0.615 | 1.5E-09 |
|
disease | 0.300 | None | 1.000 | 1 | 0 | 2008 | 2008 |